By Sam Boughedda Biopharmaceutical company Axsome Therapeutics (NASDAQ:AXSM) surged Friday after it announced that the U.S. Food and Drug Administration (FDA) has approved Auvelity...
By Amruta Khandekar (Reuters) -Axsome Therapeutics Inc on Friday gained U.S. approval for its treatment for depression, giving more than 20 million Americans affected by the...
Investing in mid-cap stocks is essential for investors who prefer a diversified portfolio. These stocks offer a middle ground with regard to the risks and rewards when compared to...
Axsome Therapeutics (NASDAQ:AXSM), Inc. AXSM has been struggling lately, but the selling pressure may be coming to an end soon. That is because AXSM recently saw a Hammer Chart...
Axsome Therapeutics (NASDAQ:AXSM), Inc. AXSM announced that it plans to submit a new drug application (NDA) for its pipeline candidate, AXS-14, in the fourth quarter of 2022. The...
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is developing novel therapies for central nervous system (CNS) disorders for which there are limited treatment options. It is developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians. The Company's CNS portfolio includes four product candidates, such as AXS-05, AXS-07, AXS-12, and AXS-14. AXS-05 is being developed for the treatment of major depressive disorder (MDD), Alzheimer's disease agitation (AD agitation), and smoking cessation. AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine. AXS-12 is an investigational medicine in development for the treatment of narcolepsy. The Company also provides Sunosi, which is dual-acting dopamine and norepinephrine reuptake inhibitor indicated to improve wakefulness in adult patients.